Peggy Scherle Prelude Therapeutics Inc (PRLD) insider trading activity

Peggy Scherle is Chief Scientific Officer of Prelude Therapeutics Inc. Currently has a direct ownership of 172,920 shares of PRLD, which is worth approximately $224,796. The most recent transaction as insider was on Aug 27, 2021, when has been sold 6,014 shares (Common Stock) at a price of $36.21 per share, resulting in proceeds of $217,767. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 173K

0% 3M change

0% 12M change

Total Value Held $224,796

Peggy Scherle Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 27 2021	SELL Open market or private sale	$217,767 $36.21 p/Share	6,014 Reduced 3.36%	172,920 Common Stock
Aug 27 2021	BUY Exercise of conversion of derivative security	$8,600 $1.43 p/Share	6,014 Added 3.25%	178,934 Common Stock
Aug 26 2021	SELL Open market or private sale	$59,823 $35.19 p/Share	1,700 Reduced 0.97%	172,920 Common Stock
Aug 26 2021	BUY Exercise of conversion of derivative security	$2,431 $1.43 p/Share	1,700 Added 0.96%	174,620 Common Stock
Aug 13 2021	SELL Open market or private sale	$80,170 $35.07 p/Share	2,286 Reduced 1.3%	172,920 Common Stock
Aug 13 2021	BUY Exercise of conversion of derivative security	$3,795 $1.66 p/Share	2,286 Added 1.29%	175,206 Common Stock
Jul 27 2021	SELL Open market or private sale	$715,400 $35.77 p/Share	20,000 Reduced 10.37%	172,920 Common Stock
Jul 27 2021	BUY Exercise of conversion of derivative security	$28,600 $1.43 p/Share	20,000 Added 9.39%	192,920 Common Stock
May 07 2021	SELL Open market or private sale	$411,000 $41.1 p/Share	10,000 Reduced 5.47%	172,920 Common Stock
May 07 2021	BUY Exercise of conversion of derivative security	$14,300 $1.43 p/Share	10,000 Added 5.18%	182,920 Common Stock
Apr 08 2021	SELL Open market or private sale	$177,375 $38.31 p/Share	4,630 Reduced 2.61%	172,920 Common Stock
Apr 08 2021	BUY Grant, award, or other acquisition	$6,621 $1.43 p/Share	4,630 Added 2.54%	177,550 Common Stock
Apr 07 2021	SELL Open market or private sale	$609,421 $39.65 p/Share	15,370 Reduced 8.16%	172,920 Common Stock
Apr 07 2021	BUY Grant, award, or other acquisition	$21,979 $1.43 p/Share	15,370 Added 7.55%	188,290 Common Stock

Peggy Scherle

Chief Scientific Officer

Wilmington, DE

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRLD shares.

Notify only if

Value

Insider Trading

Get notified when an Prelude Therapeutics Inc insider buys or sells PRLD shares.

Notify only if

Operation

Value

Type

News

Receive news related to Prelude Therapeutics Inc

Track Activities on PRLD

Account